Effectiveness of ICS/LABA and LAMA/LABA in COPD due to Biomass

A. Ramírez-Venegas, F. Montiel-Lopez, R. Robles-Hernández, Bartolome R Celli, R. Sansores, Maricruz Cassou-Martínez, J. L. P. Lara-Albisua, Claudia González-González, M. E. Mayar-Maya, Aloisa P. Hernández-Morales, R. Hernández-Zenteno, R. Falfán-Valencia, Ireri Thirión-Romero, Oliver Pérez-Bautista, Rogelio Pérez-Padilla
{"title":"Effectiveness of ICS/LABA and LAMA/LABA in COPD due to Biomass","authors":"A. Ramírez-Venegas, F. Montiel-Lopez, R. Robles-Hernández, Bartolome R Celli, R. Sansores, Maricruz Cassou-Martínez, J. L. P. Lara-Albisua, Claudia González-González, M. E. Mayar-Maya, Aloisa P. Hernández-Morales, R. Hernández-Zenteno, R. Falfán-Valencia, Ireri Thirión-Romero, Oliver Pérez-Bautista, Rogelio Pérez-Padilla","doi":"10.1183/23120541.00154-2024","DOIUrl":null,"url":null,"abstract":"Chronic obstructive pulmonary disease due to biomass exposure (COPD-B) is highly prevalent in low-and middle-income countries, and there are no clinical trials designed to evaluate the effectiveness of the treatments currently recommended for patients with COPD due to cigarette smoking (COPD-C). The purpose of the study was to compare the efficacy of Fluticasone Furoate/Vilanterol (FF/V) 100/25 μg and Umeclidinium/Vilanterol (U/V) 62.5/25 μg on the rate of exacerbations, the time to first exacerbation, on dyspnea, health-related quality of life (HRQL) and forced expiratory volume during the first second (FEV1) and inspiratory capacity (IC) during six months in patients with COPD-B and COPD-C, at a third level referral center in Mexico City.A pilot, single-center, open-label, parallel-group study included 132 patients with a history of at least two exacerbations. They were randomised to receive one of four treatment groups: 33 COPD-B patients received FF/VI 100/25 μg, 31 COPD-B patients received UMEC/VI 62.5/25 μg, 34 COPD-C patients received FF/V, and 34 received UMEC/VI.There were no differences in exacerbation rates between patients receiving FF/VI or UMEC/VI in either the COPD-B [0.07 (CI 95%, 0.03–0.13), 0.06 (CI 95%, 0.03–0.12] or COPD-C group [0.06 (CI 95%, 0.04–0.11); 0.08 (CI 95%, 0.05–0.13)], nor in the time of first exacerbation, nor FEV1and IC. All groups showed improvement in dyspnea and HRQL, independently of medication used.Among patients with COPD-B and COPD-C with a history of exacerbation, FF/VI was equally effective as UMEC/VI in preventing exacerbations and improving dyspnea and HRQL.","PeriodicalId":504874,"journal":{"name":"ERJ Open Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ERJ Open Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/23120541.00154-2024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic obstructive pulmonary disease due to biomass exposure (COPD-B) is highly prevalent in low-and middle-income countries, and there are no clinical trials designed to evaluate the effectiveness of the treatments currently recommended for patients with COPD due to cigarette smoking (COPD-C). The purpose of the study was to compare the efficacy of Fluticasone Furoate/Vilanterol (FF/V) 100/25 μg and Umeclidinium/Vilanterol (U/V) 62.5/25 μg on the rate of exacerbations, the time to first exacerbation, on dyspnea, health-related quality of life (HRQL) and forced expiratory volume during the first second (FEV1) and inspiratory capacity (IC) during six months in patients with COPD-B and COPD-C, at a third level referral center in Mexico City.A pilot, single-center, open-label, parallel-group study included 132 patients with a history of at least two exacerbations. They were randomised to receive one of four treatment groups: 33 COPD-B patients received FF/VI 100/25 μg, 31 COPD-B patients received UMEC/VI 62.5/25 μg, 34 COPD-C patients received FF/V, and 34 received UMEC/VI.There were no differences in exacerbation rates between patients receiving FF/VI or UMEC/VI in either the COPD-B [0.07 (CI 95%, 0.03–0.13), 0.06 (CI 95%, 0.03–0.12] or COPD-C group [0.06 (CI 95%, 0.04–0.11); 0.08 (CI 95%, 0.05–0.13)], nor in the time of first exacerbation, nor FEV1and IC. All groups showed improvement in dyspnea and HRQL, independently of medication used.Among patients with COPD-B and COPD-C with a history of exacerbation, FF/VI was equally effective as UMEC/VI in preventing exacerbations and improving dyspnea and HRQL.
ICS/LABA 和 LAMA/LABA 在慢性阻塞性肺病中的疗效,因生物量而异
生物质暴露引起的慢性阻塞性肺病(COPD-B)在中低收入国家发病率很高,目前还没有针对吸烟引起的慢性阻塞性肺病(COPD-C)患者推荐的治疗方法的有效性进行评估的临床试验。这项研究的目的是比较糠酸氟替卡松/维兰特罗(FF/V)100/25 μg和优甲乐/维兰特罗(U/V)62.在墨西哥城的一家三级转诊中心进行的一项试验性、单中心、开放标签、平行组研究纳入了 132 名至少有两次病情加重病史的患者。他们被随机分配到四个治疗组中的一组:33 名 COPD-B 患者接受 FF/VI 100/25 μg,31 名 COPD-B 患者接受 UMEC/VI 62.5/25 μg,34 名 COPD-C 患者接受 FF/V,34 名接受 UMEC/VI。无论是 COPD-B 组[0.07(CI 95%,0.03-0.13),0.06(CI 95%,0.03-0.12)]还是 COPD-C 组[0.06(CI 95%,0.04-0.11);0.08(CI 95%,0.05-0.13)],接受 FF/VI 或 UMEC/VI 治疗的患者在病情恶化率、首次病情恶化时间、FEV1 和 IC 方面均无差异。在有病情加重病史的 COPD-B 和 COPD-C 患者中,FF/VI 与 UMEC/VI 在预防病情加重、改善呼吸困难和 HRQL 方面效果相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信